Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
about
Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-AnalysisIs screening and surveillance for early detection of gastric cancer needed in Korean Americans?Kyoto global consensus report on Helicobacter pylori gastritisA review of the past, present, and future directions of neoplasiaComing of Age in the Life ofNeoplasia: Where We Have Been and Where We Are GoingChronic gastritis.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade PortuGastric cancer in a Caucasian population: role of pepsinogen C genetic variants.Screening for and surveillance of gastric cancer.Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous diseaseRationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.Health economic assessment for screening of gastric cancer in a high risk population in northeastern china.Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers.Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies.Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.Screening and Preventive Strategies in Esophagogastric Cancer.Pepsinogen-II 100 bp ins/del gene polymorphism and its elevated circulating levels are associated with gastric cancer, particularly with Helicobacter pylori infection and intestinal metaplasia.Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis.Decrease in PSCA expression caused by Helicobacter pylori infection may promote progression to severe gastritis.Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.Immune responses against Helicobacter pylori in gastric cancer patients and in risk groups for gastric cancer.Age-Specific Gastric Cancer Risk Indicated by the Combination of Helicobacter pylori Sero-Status and Serum Pepsinogen Levels.Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portug
P2860
Q26778122-0877982B-FC97-4ADB-A21D-F8DA798BDD22Q26778331-EE32D7E7-0D31-4BC6-A6BB-36AB7B6FC4BCQ26799430-37BE3A31-620D-4C85-81A1-F914D9E9CC2DQ28389391-A26112C7-2FD5-48EE-858C-404490CAEFFCQ28389985-B868CEB8-64FD-4348-92CE-B1A2B9A373A4Q28395095-04B48CC8-48F3-44BE-B01B-8DC29F02BE0DQ30374031-F4CA5637-D40F-4308-80FA-5E7A143953D2Q30426539-E5EE79E5-81EA-4F32-92F5-D5711300092AQ33866182-ADD44C9D-C06F-4862-8F6B-AFC66FB16EE9Q34326563-0E5B2F41-A0F7-4702-9463-E2ABDD885D9AQ34978232-6ABCEE0D-5799-4239-A060-38D64A4FBFA0Q35755917-E0FC85E1-8FEE-42DD-9437-77459E29C1A7Q36654631-4D00B296-F4BC-4509-ABEC-9439F2B22DAAQ36693173-CF14E7C1-1FA1-4A8D-9556-9BC0A4CCFED6Q36996612-BE6964F0-45F2-4D6E-9DED-DF8827D78B3CQ38244069-ED96DFEE-5962-4E29-A7DC-3FF661BDBB70Q39171528-8C366578-162F-4583-8B0E-83AEA72AD828Q40943310-0F883B85-2001-47E9-8319-2693D239638CQ47106951-975B7C58-EC82-4304-A4C7-BDB233D44D66Q47438971-FCB5A5D8-4BA7-4053-80A0-C90F7A97A216Q49499639-5BF15C5C-2030-4F00-84EF-460C8720EF49Q50465037-4C908F5D-3F19-427C-9F3E-2128BFE550A6Q51303433-05AD664C-0557-47FB-96AD-346F2195B73DQ54858925-29FC3095-DD4C-48A8-90CA-F07C8AE65D13Q55194995-B6FC1D66-93FB-4FF7-904C-D99C6906E2A4Q57698678-C183BAAE-27B8-480E-8644-D73CA21B209D
P2860
Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@ast
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@en
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@nl
type
label
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@ast
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@en
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@nl
prefLabel
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@ast
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@en
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Validity of serum pepsinogen I ...... l-type gastric adenocarcinoma.
@en
P2093
Altamiro da Costa-Pereira
Helena Lomba-Viana
Luís Moreira-Dias
Mateus Guilherme
Nuno Abreu
Rafael Lomba-Viana
P2860
P304
P356
10.1593/NEO.03505
P577
2004-09-01T00:00:00Z